Brett Hagen - Allovir Chief Officer
| ALVRDelisted Stock | USD 9.81 0.15 1.55% |
Insider
Brett Hagen is Chief Officer of Allovir
| Age | 52 |
| Phone | 617 433 2605 |
| Web | https://www.allovir.com |
Brett Hagen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brett Hagen against Allovir stock is an integral part of due diligence when investing in Allovir. Brett Hagen insider activity provides valuable insight into whether Allovir is net buyers or sellers over its current business cycle. Note, Allovir insiders must abide by specific rules, including filing SEC forms every time they buy or sell Allovir'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brett Hagen over three months ago Disposition of 301 shares by Brett Hagen of Allovir at 0.8148 subject to Rule 16b-3 | ||
Brett Hagen over six months ago Disposition of 5045 shares by Brett Hagen of Allovir at 5.6398 subject to Rule 16b-3 | ||
Brett Hagen over six months ago Disposition of 1692 shares by Brett Hagen of Allovir at 0.7348 subject to Rule 16b-3 | ||
Brett Hagen over six months ago Disposition of 5045 shares by Brett Hagen of Allovir at 5.6398 subject to Rule 16b-3 |
Allovir Management Efficiency
The company has return on total asset (ROA) of (0.3653) % which means that it has lost $0.3653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8033) %, meaning that it created substantial loss on money invested by shareholders. Allovir's management efficiency ratios could be used to measure how well Allovir manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jacquelyn JD | Cullinan Oncology LLC | 47 | |
| Charles Newton | Lyell Immunopharma | 53 | |
| Jc MD | Adagene | 60 | |
| Eric Easom | AN2 Therapeutics | 57 | |
| MD MBA | 4D Molecular Therapeutics | 64 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 66 | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| Craig MD | Agios Pharm | 72 | |
| MSc MBA | AnaptysBio | 48 | |
| JD Esq | 4D Molecular Therapeutics | 73 | |
| Stephen Hill | Lyell Immunopharma | 54 | |
| Elizabeth Montgomery | Black Diamond Therapeutics | 53 | |
| Jillian Connell | Merus BV | N/A | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Richard MD | Lyell Immunopharma | 73 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| MD FACP | AN2 Therapeutics | 77 | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| BS CPA | Inhibrx | 42 | |
| Hunter MD | Aerovate Therapeutics | 59 | |
| Erick MD | Acrivon Therapeutics, Common | 67 | |
Management Performance
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.37 |
Allovir Leadership Team
Elected by the shareholders, the Allovir's board of directors comprises two types of representatives: Allovir inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allovir. The board's role is to monitor Allovir's management team and ensure that shareholders' interests are well served. Allovir's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allovir's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sonia Choi, Senior Relations | ||
| Agustin MD, Advisor | ||
| Dana MBA, VP Operations | ||
| Ann Leen, Chief Officer | ||
| Cintia PharmD, Chief Officer | ||
| David Hallal, Executive Board | ||
| Jeroen Beek, Consultant | ||
| Diana MD, CEO Director | ||
| Ugo Perlingieri, Head Operations | ||
| Brett Hagen, Chief Officer | ||
| Edward JD, General Secretary | ||
| Dana Alexander, Senior Operations |
Allovir Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allovir a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | (69.57 M) | ||||
| Shares Outstanding | 115.36 M | ||||
| Shares Owned By Insiders | 49.11 % | ||||
| Shares Owned By Institutions | 42.94 % | ||||
| Number Of Shares Shorted | 64.61 K | ||||
| Price To Book | 0.43 X | ||||
| Gross Profit | 165 K | ||||
| EBITDA | (65.44 M) |
Pair Trading with Allovir
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.Moving against Allovir Stock
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allovir. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Allovir Stock
If you are still planning to invest in Allovir check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Allovir's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |